ES3053333T3 - Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders - Google Patents

Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders

Info

Publication number
ES3053333T3
ES3053333T3 ES14731261T ES14731261T ES3053333T3 ES 3053333 T3 ES3053333 T3 ES 3053333T3 ES 14731261 T ES14731261 T ES 14731261T ES 14731261 T ES14731261 T ES 14731261T ES 3053333 T3 ES3053333 T3 ES 3053333T3
Authority
ES
Spain
Prior art keywords
prophylaxis
treatment
movement disorders
hyperkinetic movement
therapeutic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14731261T
Other languages
English (en)
Inventor
Batalla Núria Gavaldà
Boronat Raúl Insa
Bolano Núria Reig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Som Innovation Biotech SA
Original Assignee
Som Innovation Biotech SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3053333(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Som Innovation Biotech SA filed Critical Som Innovation Biotech SA
Application granted granted Critical
Publication of ES3053333T3 publication Critical patent/ES3053333T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al uso de (RS)-[2-(3,4-dimetoxifenil)etil][2-hidroxi-3-(3-metilfenoxi)propil]amina que tiene la fórmula (IA), o una sal farmacéuticamente aceptable de la misma para la formulación de una composición farmacéutica, útil para la profilaxis y/o el tratamiento de trastornos del movimiento hipercinético asociados con la enfermedad de Huntington, la enfermedad de Wilson, el síndrome de Tourette, el síndrome de piernas inquietas y la discinesia tardía. (Traducción automática con Google Translate, sin valor legal)
ES14731261T 2013-06-19 2014-06-18 Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders Active ES3053333T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382230 2013-06-19
PCT/EP2014/062786 WO2014202646A1 (en) 2013-06-19 2014-06-18 Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders

Publications (1)

Publication Number Publication Date
ES3053333T3 true ES3053333T3 (en) 2026-01-21

Family

ID=48672545

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14731261T Active ES3053333T3 (en) 2013-06-19 2014-06-18 Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders

Country Status (20)

Country Link
US (2) US9789072B2 (es)
EP (1) EP3010543B1 (es)
JP (1) JP6476174B2 (es)
KR (1) KR102254542B1 (es)
CN (1) CN105658238B (es)
AU (1) AU2014283319B2 (es)
BR (1) BR112015031835B1 (es)
CA (1) CA2915811C (es)
CL (1) CL2015003679A1 (es)
DK (1) DK3010543T3 (es)
ES (1) ES3053333T3 (es)
HK (1) HK1223014A1 (es)
IL (1) IL243192B (es)
MX (1) MX366353B (es)
PL (1) PL3010543T3 (es)
PT (1) PT3010543T (es)
RU (1) RU2685502C2 (es)
SG (1) SG11201510451RA (es)
WO (1) WO2014202646A1 (es)
ZA (1) ZA201600312B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41557A (fr) * 2015-02-18 2017-12-26 Auspex Pharmaceuticals Inc Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2
IL309802A (en) * 2017-09-21 2024-02-01 Neurocrine Biosciences Inc High dose valbenazine formulation and related preparations, methods and kits
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790165A (fr) * 1971-12-14 1973-02-15 Parke Davis & Co Nouveaux aminoalcanols et procede pour les preparer
ES2569483T3 (es) 2007-06-21 2016-05-11 Amgen Inc. Métodos para sintetizar cinacalcet y sales del mismo
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
US8197858B2 (en) 2009-02-06 2012-06-12 Mark John Zamoyski Bone microenvironment modulated seizure treatments
UA113165C2 (xx) 2011-03-01 2016-12-26 Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
PT2560631E (pt) * 2011-03-01 2014-02-24 Pharnext Terapia à base de baclofeno e acamprosato de distúrbios neurológicos

Also Published As

Publication number Publication date
BR112015031835A2 (pt) 2017-07-25
MX366353B (es) 2019-07-05
BR112015031835B1 (pt) 2022-12-13
MX2015018040A (es) 2016-08-03
SG11201510451RA (en) 2016-01-28
CN105658238B (zh) 2019-07-12
IL243192A0 (en) 2016-02-29
JP2016522235A (ja) 2016-07-28
US9789072B2 (en) 2017-10-17
RU2016101152A (ru) 2017-07-24
CN105658238A (zh) 2016-06-08
EP3010543A1 (en) 2016-04-27
HK1223014A1 (zh) 2017-07-21
WO2014202646A1 (en) 2014-12-24
PT3010543T (pt) 2025-11-28
DK3010543T3 (da) 2025-12-01
JP6476174B2 (ja) 2019-02-27
EP3010543B1 (en) 2025-11-05
KR20160055121A (ko) 2016-05-17
CA2915811C (en) 2021-08-31
AU2014283319B2 (en) 2019-07-25
US20160158167A1 (en) 2016-06-09
AU2014283319A1 (en) 2016-02-11
BR112015031835A8 (pt) 2019-12-31
IL243192B (en) 2019-12-31
NZ715951A (en) 2021-03-26
RU2685502C2 (ru) 2019-04-19
PL3010543T3 (pl) 2026-01-19
ZA201600312B (en) 2022-12-21
KR102254542B1 (ko) 2021-05-24
CL2015003679A1 (es) 2016-09-02
US20180042869A1 (en) 2018-02-15
CA2915811A1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
BR112015020453A8 (pt) "formas de dosagem de liberação prolongada orais de tofacitinibe e uso de tofacitinibe
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
ME02910B (me) Spojevi tetrahidropirolotiazina
AR077629A1 (es) Mimetico de smac
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
AR094553A1 (es) Formas de oxadiazolpirazina
UY36124A (es) Derivados de carboxamida
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib
EA201692298A1 (ru) Производные карбоксамидов
BR112015023878A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
AR090975A1 (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
ES3053333T3 (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
CR20150327A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.